En Es
Categories

Industry News

ZOLL Medical Completes Acquisition of Cardiac Science

By HospiMedica International staff writers
10 Sep 2019

Image: ZOLL Medical has completed its acquisition of Cardiac Science (Photo courtesy of iStock).ZOLL Medical Corporation (Chelmsford, MA, USA), which manufactures medical devices and related software solutions, has completed the previously announced acquisition of Cardiac Science Corporation (Waukesha, WI, USA), a provider of automated external defibrillators (AEDs), related services, and accessories.

ZOLL, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. Cardiac Science develops, manufactures, and markets AEDs and related parts, components, and accessories. The company also provides a comprehensive portfolio of training, maintenance, and support services for AED customers.

With the completion of the acquisition, Cardiac Science will become part of ZOLL’s Resuscitation division, but will continue manufacturing in its facility in Deerfield, Wisconsin. ZOLL will continue to promote, market, and supply the Powerheart line of AEDs and Rescue Ready services as well as ZOLL AEDs and PlusTrac program management.

“We are excited about the alignment of our two companies and our combined ability to place lifesaving technology into the hands of more lay rescuers and first responders during medical emergencies,” said Elijah A. White, President of ZOLL Resuscitation. “This acquisition fits well into ZOLL’s vision of providing integrated, innovative acute and resuscitation care for all.”

“Cardiac Science and ZOLL both provide proven AED solutions to broad segments of the public safety market,” added White. “With Cardiac Science now part of ZOLL, we’ll be able to offer our customers more choices and a stronger AED program management infrastructure to ensure that both families of AEDs are ready when needed.”



E-mail Print
FaceBook Twitter Google+ Linked in

Zoll Medical

Develops and markets medical devices and software solutions for advance emergency care, including products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management
More info

Additional news

19 Feb 2020
New Artificial Intelligence Algorithm Boosts Quality of Brain Magnetic Resonance Imaging
 Researchers from the ICAI Group -Computational Intelligence and Image Analysis- of the University of Malaga {(UMA) Málaga, Spain) have designed a method that is capable of improving brain images obtained through magnetic resonance imaging using artificial intelligence (AI). The new model manages to increase image quality from low resolution to high resolution without distorting the patients' brain structures, using a deep learning artificial neural network - a model based on the functioning of the human brain - that "learns" this process.
Read More
17 Feb 2020
New System Combines Advanced Optical Imaging with AI Algorithm to Accurately Identify Brain Tumors
 Researchers from the NYU Grossman School of Medicine (New York, NY, USA) and the University of Michigan (Ann Arbor, MI, USA) have developed a novel method of combining advanced optical imaging with an artificial intelligence (AI) algorithm to produce accurate, real-time intraoperative diagnosis of brain tumors. The imaging technique, stimulated Raman histology (SRH), reveals tumor infiltration in human tissue by collecting scattered laser light, illuminating essential features not typically seen in standard histologic images. The microscopic images are then processed and analyzed with AI, allowing surgeons to see a predicted brain tumor diagnosis in less than three minutes. Using the same technology, after the resection, the surgeons can accurately detect and remove otherwise undetectable tumor.
Read More
10 Feb 2020
Global Medical Robotics Market to Reach USD 13.90 Billion by 2026
 The global medical robotics market is projected to grow at a double-digit CAGR from 2019 to 2026 to reach USD 13.90 billion by 2026, driven by the increasing demand for minimally invasive surgery, rising prevalence of gynecology, urology and orthopedic disorders, increasing aging population, technological innovations, growing adoption of medical robots among the population and increasing clinical trials.
Read More
04 Feb 2020
Patient Handling Equipment Market to Reach USD 12.6 Billion by 2024
 The global patient handling equipment market is projected to grow at a CAGR of 7.2% from USD 8.9 billion in 2019 to USD 12.6 billion by 2024, driven mainly by the rising geriatric population, high risk of injuries to caregivers during manual handling of patients, and regulations for ensuring the safety of healthcare personnel during manual lifting processes. However, continued difficulties in handling bariatric patients are expected to limit the market growth to some extent.
Read More
30 Jan 2020
Study Finds Most Healthcare Institutions Plan to Use AI and Develop Own AI Algorithm
 A new study of healthcare professionals has revealed that Artificial Intelligence (AI) is widely expected to drive important benefits across the health system, from increasing efficiency to improving patient outcomes, but may also be the key to making healthcare more human. AI’s benefits range from increasing the amount of time clinicians can spend with patients and on cross-care team collaboration to enhancing the ability to deliver preventative care.
Read More
30 Jan 2020
Quest Diagnostics Acquires Blueprint Genetics
 Quest Diagnostics (Secaucus, NJ, USA), a provider of diagnostic information services, has acquired Blueprint Genetics (Helsinki, Finland), a specialty genetic testing company with expertise in gene variant interpretation based on next generation sequencing (NGS) and proprietary bioinformatics. Together, Quest and Blueprint Genetics will broaden access to actionable insights in genetic and rare diseases, improving patient care and pharmaceutical drug research and development.
Read More
27 Jan 2020
JNJ Acquires Remaining Stake in Verb Surgical
 Johnson & Johnson (New Brunswick, N.J., USA) has acquired the remaining stake in Verb Surgical Inc. (Santa Clara, CA, USA), following a successful strategic collaboration with Verily, an Alphabet company. Verb Surgical's robotics and data science capabilities, combined with Johnson & Johnson's health care leadership and global reach, aim to make medical interventions smarter, less invasive and more personalized.
Read More
22 Jan 2020
Global Point of Care Testing (POCT) Market to Reach USD 46.7 Billion by 2024
 The global point of care testing (POCT) market is expected to surpass USD 37 billion by 2025, driven mainly by the migration of POCT from the hospital environment to a range of medical environments, including the workplace, home, disaster care and most recently, convenience clinics. POCT now appears to be headed for a bigger role in diagnosis and monitoring patient care. Additionally, growing awareness about early disease diagnosis and prevention has stimulated the demand for POCT for detecting cancer and infectious disease in the early stages. Moreover, the rising incidence of infectious diseases and chronic conditions, such as cardiovascular diseases and diabetes in the developing countries such as India and China, is stimulating the demand for POCT services.
Read More
16 Jan 2020
Radiomic Algorithm Predicts if Patient’s Cancer Can Return 10 Years After Treatment
 A new study by researchers at Penn Medicine (Philadelphia, PA, USA) has found that Magnetic Resonance Imaging (MRI) and an emerging field of medicine called radiomics — which uses algorithms to extract a large amount of features from medical images — could help to characterize the heterogeneity of cancer cells within a tumor and allow for a better understanding of the causes and progression of a person’s individual disease.
Read More
Copyright © 2000-2020 TradeMed.com. All rights reserved. | Terms And Conditions